The Effect of Drug on the Patency Rate of Fistulae

The Effect of Antiplatelet Drugs on the Patency Rate of Arterio-venous Fistulae in Hemodialysis Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009292220N3

Enrollment

501

Registered

2010-11-06

Start date

2003-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choronic renal failure. End-stage renal disease

Interventions

Intervention 1: 75 milligram /day Dipyridamol after creation arterio-venous fistulae. Intervention 2: 325 milligram /day Aspirin after creation arterio-venous fistulae. Intervention 3: multi vitamin

Prevention

Placebo

75 milligram /day Dipyridamol after creation arterio-venous fistulae

325 milligram /day Aspirin after creation arterio-venous fistulae

multi vitamin tablet after creation arterio-venous fistulae

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All end stage renal disease (ESRD) patients who needed Arterio-venous Fistulae (AVF) for hemodilysis. Exclusion criteria: bleeding tendency, active peptic ulcer disease, pregnancy, lactation, use of anticoagulant and or non steroidal anti-inflammatory drugs, hepatic insufficiency and history of significant side effects from aspirin or dipyridamol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patency of Arterio-venous fistulae according age ,sex ,site. Timepoint: weekly. Method of measurement: presense or absence Thrill or bruit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad Reza Sobhiyeh

Shahid Beheshti University of Medical Sciences

mreza_sobhiyeh@yahoo.com , mozafar@sbmu.ac.ir+98 21 2271 8000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026